helicobacter%20pylori%20infection
HELICOBACTER PYLORI INFECTION
Helicobacter pylori is a spiral-shaped gram-negative bacterium involved in the development of gastritis, duodenal and gastric ulcers, and gastric cancer.
Infection is strongly associated with the development of gastric epithelial and lymphoid malignancies.
Acute infection is mostly asymptomatic and is acquired through human-to-human contact via gastro-oral and fecal-oral routes.
Adaptability in gastric conditions and production of urease allow it to colonize the stomach.

Follow Up

Patient should be re-tested after a minimum of 4 weeks after treatment

  • It is advisable to confirm eradication of H pylori with a post-treatment UBT, monoclonal stool test or upper endoscopy
    • Antisecretory drugs especially PPIs should be discontinued at least 1-2 weeks prior to post-test, while Bismuth compounds and antibiotics should be stopped at least 4 weeks prior to test 
  • Patients with either gastric ulcers or complicated duodenal ulcers should have a repeat endoscopy and biopsy, UBT, or stool antigen test to rule out malignancy
  • In patients with persistent H pylori infection, a culture and sensitivity may be done before retreatment, except when considering a Bismuth-based quadruple therapy
  • Serology is not used in determining treatment response
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 19 Jun 2019
Adding periodontal therapy (periotherapy) to standard triple antibiotic therapy targeting Helicobacter (H.) pylori may reduce the risk of recurrence of H. pylori infections, a new study shows, suggesting a promising approach for managing H. pylori infection.
Elaine Soliven, 23 Jan 2019
Older patients receiving treatment for ulcerative colitis (UC) were more likely to experience adverse events (AEs) compared with their younger counterparts, according to a study presented at AIBD 2018.